Palvella Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PVLA | TARS | LKFT | BHVN | MANE | CGEM | |
|---|---|---|---|---|---|---|
| Market cap | 1.94B | 3.48B | 1.94B | 1.78B | 5.11B | 918.80M |
| P/E (TTM) | — | — | 2.8 | — | — | — |
| Forward P/E | -17.9 | -206.7 | -24.9 | -6.3 | -45.6 | -5.9 |
| Price/book | 8.9 | 9.3 | 10.5 | 145.8 | 6.3 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +82.78% | +6.54% | −11.73% | −29.11% | +224.24% | +93.15% |
| Today | −3.16% | +1.69% | −0.54% | −2.24% | −6.49% | −3.73% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PVLA news ›Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
Comprehensive Real-World Claims Analysis Identifies an Estimated 154,986 Patients Diagnosed With DSAP in the U.S. SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours In August…
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger (NASDAQ:PVLA)
Palvella Therapeutics advances QTORIN rapamycin for microcystic lymphatic malformations with strong Phase 3 data. Read more on PVLA stock here. - Palvella Therapeutics, Inc. advances QTORIN rapamycin for microcystic lymphatic…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
mychesco.com1
-
seekingalpha.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.